Genprex

Investor

Downloads


Investor Presentation

Review our latest corporate presentation with an overview of company highlights, recent milestones and clinical updates.

Download

2024 AACR Poster – Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing Non-Small Cell Lung Carcinoma can induce cellular apoptosis

We’re passionate about the work we’re doing to fight cancer and diabetes, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.

Download

2024 AACR Poster – Mechanism of NPRL2 gene therapy induced anti-tumor immunity in KRAS/STK11mt aPD1 resistant metastatic NSCLC

We’re passionate about the work we’re doing to fight cancer and diabetes, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.

Download

2024 AACR Poster – Tumor Suppressor Gene TUSC2 suppresses energy metabolism in lung cancer cells with opposite effects in normal bronchial epithelial cells

We’re passionate about the work we’re doing to fight cancer and diabetes, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.

Download

AACR-NCI-EORTC International Conference 2023 – Completion of Acclaim-1 Dose Escalation: Recommended Phase 2 Dose of Quaratusugene Ozeplasmid Gene Therapy and Osimertinib

Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®

Download

AACR-NCI-EORTC International Conference 2023 – TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice

Preclinical results show that REQORSA® in combination with a checkpoint inhibitor has anti-tumor activity in a humanized mouse model of small cell lung cancer (SCLC)

Download

2023 AACR Abstract – NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanized mouse model

The abstract reports NPRL2 gene therapy induces effective anti-tumor activity in non-small cell lung cancer pembrolizumab resistant tumors in a humanized mouse model and provides preclinical validation of the ONCOPREX® Nanoparticle Delivery System with a second tumor suppressor gene

Download

ATTD 2023 – Pancreatic Intraductal Infusion of Adeno-Associated Virus To Treat Non- Human Primates in a Toxin-Induced Diabetes Model

Data highlighting the potential of Genprex’s gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) on February 25, 2023 in Berlin, Germany.

Download

Fact Sheet

A one-page fact sheet and overview of Genprex.

Download

TUSC2 Bibliography

A bibliography of selected publications describing the TUSC2 gene.

Download

PDX1 and MAFA Bibliography

A bibliography of selected publications describing the PDX1 and MAFA genes.

Download

2021 AACR Poster – Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC – Meraz

The poster presents positive preclinical data for REQORSA in combination with Tagrisso®, demonstrating synergistic antitumor efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance.

Download

2020 International Journal of Molecular Sciences

The study found TUSC2 may be a novel target and biomarker for thyroid cancer therapy.

Download

2019 AACR KRAS and LKB1 Poster – Meraz

The poster demonstrates research and data on the efficacy of novel immunogene combinations for KRAS and LKB1 mutant NSCLC in a humanized mouse model.

Download

2019 Nature Research Scientific Reports

The study found that TUSC2 prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options.

Download

2019 AACR Hu-PDX Poster – Meraz

The poster presents positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a humanized mouse model.

Download

2012 AACR Poster – Yan

The poster describes a novel anticancer therapeutic strategy using a new class of rationally designed dual DNA alkylating/HDAC inhibitors combined with nanoparticle-mediated gene therapy targeting the DNA damage/repair pathway in human NSCLC and SCLC cells.

Download

2012 AACR Poster – Meng

The poster presents data on the synergistic antitumor activity of MK2206 and TUSC2/FUS1-nanoparticle in NSCLC.

Download